Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study

Lancet Neurology

Volumn 6, Issue 9, 2007, Pages 765-772

  Patterson, Marc C ^a   Vecchio, Darleen ^a   Prady, Helena ^b   Abel, Larry ^c   Wraith, James E ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDIARRHEAL AGENT; BENZODIAZEPINE DERIVATIVE; HYPNOTIC AGENT; MIGLUSTAT; SEDATIVE AGENT;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADOLESCENT; ADULT; ANOREXIA; ARTICLE; ATAXIA; BODY SURFACE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; DEPRESSION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; FALLING; FATIGUE; FLATULENCE; GAIT DISORDER; HEADACHE; HEARING ACUITY; HEARING IMPAIRMENT; HUMAN; HYPERREFLEXIA; INSOMNIA; LACERATION; LIMB PAIN; NAUSEA; NIEMANN PICK DISEASE; OCCUPATIONAL THERAPY; PARESTHESIA; PHYSIOTHERAPY; PRIORITY JOURNAL; PTOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SACCADIC EYE MOVEMENT; SIDE EFFECT; SINUSITIS; SPASTICITY; SPEECH THERAPY; TREMOR; VOMITING; WEIGHT REDUCTION;

1-DEOXYNOJIRIMYCIN; ADOLESCENT; ADULT; AGE FACTORS; ANALYSIS OF VARIANCE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DEGLUTITION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; NIEMANN-PICK DISEASE, TYPE C; RETROSPECTIVE STUDIES; SACCADES; SEVERITY OF ILLNESS INDEX;

EID: 34547753513     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(07)70194-1     Document Type: Article

References (36)

1. Pentchev P., Comly M., Kruth H., et al. Group C Niemann-Pick disease: faulty regulation of low-density lipoprotein uptake and cholesterol storage in cultured fibroblasts. Faseb J 1 (1987) 40-45
2. Liscum L., and Sturley S. Intracellular trafficking of Niemann-Pick C proteins 1 and 2: obligate components of subcellular lipid transport. Biochim Biophys Acta 1685 (2004) 22-27
3. Millat G., Marcais C., Rafi M., et al. Niemann-Pick C1 disease: the I1061T substitution is a frequent mutant allele in patients of Western European descent and correlates with a classic juvenile phenotype. Am J Hum Genet 65 (1999) 1321-1329
4. Wenger D., Barth G., and Githens J. Nine cases of sphingomyelin lipidosis, a new variant in Spanish-American Children. Juvenile variant of Niemann-Pick Disease with foamy and sea-blue histiocytes. Am J Dis Child 131 (1977) 955-961
5. Winsor E., and Welch J. Genetic and demographic aspects of Nova Scotia Niemann-Pick disease (type D). Am J Hum Genet 30 (1978) 530-538
6. Carstea E., Morris J., Coleman K., et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 277 (1997) 228-231
7. Naureckiene S., Sleat D., Lackland H., et al. Identification of HE1 as the second gene of Niemann-Pick C disease. Science 290 (2000) 2298-2301
8. Frolov A., Srivastava K., Daphna-Iken D., Traub L., Schaffer J., and Ory D. Cholesterol overload promotes morphogenesis of a Niemann-Pick C (NPC)-like compartment independent of inhibition of NPC1 or HE1/NPC2 function. J Biol Chem 276 (2001) 46414-46421
9. Walkley S. Secondary accumulation of gangliosides in lysosomal storage disorders. Semin Cell Dev Biol 15 (2004) 433-444
10. Walkley S., Siegel D., and Dobrenis K. GM2 ganglioside and pyramidal neuron dendritogenesis. Neurochem Res 20 (1995) 1287-1299
11. Karten B., Campenot R., Vance D., and Vance J. The Niemann-Pick C1 protein in recycling endosomes of presynaptic nerve terminals. J Lipid Res 47 (2006) 504-514
12. Walkley S., and Suzuki K. Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim Biophys Acta 1685 (2004) 48-62
13. Solomon D., Winkelman A., Zee D., Gray L., and Buttner-Ennever J. Niemann-Pick type C disease in two affected sisters: ocular motor recordings and brain-stem neuropathology. Ann N Y Acad Sci 1039 (2005) 436-445
14. Patterson M. A riddle wrapped in a mystery: understanding Niemann-Pick disease, type C. Neurologist 9 (2003) 301-310
15. Sullivan D., Walterfang M., and Velakoulis D. Bipolar disorder and Niemann-Pick disease type C. Am J Psychiatry 162 (2005) 1021-1022
16. Walterfang M., Fietz M., Fahey M., et al. The neuropsychiatry of Niemann-Pick type C disease in adulthood. J Neuropsychiatry Clin Neurosci 18 (2006) 158-170
17. Oyama K., Takahashi T., Shoji Y., et al. Niemann-Pick disease type C: cataplexy and hypocretin in cerebrospinal fluid. Tohoku J Exp Med 209 (2006) 263-267
18. Patterson M., Vanier M., Suzuki K., et al. Niemann-Pick disease, type C: a lipid trafficking disorder. In: Scriver C., Beaudet A., Sly W., et al. (Eds). The Metabolic and Molecular Bases of Inherited Disease. 8th edn. (2001), McGraw-Hill, New York 3611-3633
19. Rottach K., von Maydell R., Das V., et al. Evidence for independent feedback control of horizontal and vertical saccades from Niemann-Pick type C disease. Vision Res 37 (1997) 3627-3638
20. Garbutt S., and Harris C. Abnormal vertical optokinetic nystagmus in infants and children. Br J Ophthalmol 84 (2000) 451-455
21. Neville B., Lake B., Stephens R., and Sanders M. A neurovisceral storage disease with vertical supranuclear ophthalmoplegia, and its relationship to Niemann-Pick disease. A report of nine patients. Brain 96 (1973) 97-120
22. Patterson M., and Platt F. Therapy of Niemann-Pick disease, type C. Biochim Biophys Acta 1685 (2004) 77-82
23. Platt F., Jeyakumar M., Andersson U., Dwek R., and Butters T. New developments in treating glycosphingolipid storage diseases. Adv Exp Med Biol 564 (2005) 117-126
24. Platt F., Neises G., Dwek R., and Butters T. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 269 (1994) 8362-8365
25. Brady R. Emerging strategies for the treatment of hereditary metabolic storage disorders. Rejuvenation Res 9 (2006) 237-244
26. Jeyakumar M., Dwek R., Butters T., and Platt F. Storage solutions: treating lysosomal disorders of the brain. Nat Rev Neurosci 6 (2005) 713-725
27. Zervas M., Somers K., Thrall M., and Walkley S. Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol 11 (2001) 1283-1287
28. Lachmann R., te Vruchte D., Lloyd-Evans E., et al. Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. Neurobiol Dis 16 (2004) 654-658
29. Cox T., Lachmann R., Hollak C., et al. A novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355 (2000) 1481-1485
30. Elstein D., Hollak C., Aerts J., et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 27 (2004) 757-766
31. Pastores G., Barnett N., and Kolodny E. An open-label, noncomparative study of miglustat in Type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 27 (2005) 1215-1227
32. Lengyel D., Weissert M., Schmid L., and Gottlob I. [Eye movement abnormalities as a sign for the diagnosis in Niemann-Pick disease type C]. Klin Monatsbl Augenheilkd 214 (1999) 50-52
33. Inchingolo P., and Spanio M. On the identification and analysis of saccadic eye movements-a quantitative study of the processing procedures. IEEE Trans Biomed Eng 32 (1985) 683-695
34. Roy-Byrne P., Cowley D., Radant A., Hommer D., and Greenblatt D. Benzodiazepine pharmacodynamics: utility of eye movement measures. Psychopharmacology (Berl) 110 (1993) 85-91
35. Imrie J., Dasgupta S., Besley G., et al. The natural history of Niemann-Pick disease type C in the UK. J Inherit Metab Dis 30 (2007) 51-59
36. Treiber A., Morand O., and Clozel M. The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica 37 (2007) 298-314